Details
Stereochemistry | ACHIRAL |
Molecular Formula | C12H15N3O2S |
Molecular Weight | 265.331 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCSC1=CC=C2N=C(NC(=O)OC)NC2=C1
InChI
InChIKey=HXHWSAZORRCQMX-UHFFFAOYSA-N
InChI=1S/C12H15N3O2S/c1-3-6-18-8-4-5-9-10(7-8)14-11(13-9)15-12(16)17-2/h4-5,7H,3,6H2,1-2H3,(H2,13,14,15,16)
Molecular Formula | C12H15N3O2S |
Molecular Weight | 265.331 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:05:18 UTC 2023
by
admin
on
Fri Dec 15 15:05:18 UTC 2023
|
Record UNII |
F4216019LN
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
94295
Created by
admin on Fri Dec 15 15:05:18 UTC 2023 , Edited by admin on Fri Dec 15 15:05:18 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.1.1
Created by
admin on Fri Dec 15 15:05:18 UTC 2023 , Edited by admin on Fri Dec 15 15:05:18 UTC 2023
|
||
|
CFR |
21 CFR 520.38A
Created by
admin on Fri Dec 15 15:05:18 UTC 2023 , Edited by admin on Fri Dec 15 15:05:18 UTC 2023
|
||
|
WHO-ATC |
P02CA03
Created by
admin on Fri Dec 15 15:05:18 UTC 2023 , Edited by admin on Fri Dec 15 15:05:18 UTC 2023
|
||
|
CFR |
21 CFR 520.38
Created by
admin on Fri Dec 15 15:05:18 UTC 2023 , Edited by admin on Fri Dec 15 15:05:18 UTC 2023
|
||
|
NCI_THESAURUS |
C250
Created by
admin on Fri Dec 15 15:05:18 UTC 2023 , Edited by admin on Fri Dec 15 15:05:18 UTC 2023
|
||
|
WHO-VATC |
QP52AC11
Created by
admin on Fri Dec 15 15:05:18 UTC 2023 , Edited by admin on Fri Dec 15 15:05:18 UTC 2023
|
||
|
CFR |
21 CFR 520.38B
Created by
admin on Fri Dec 15 15:05:18 UTC 2023 , Edited by admin on Fri Dec 15 15:05:18 UTC 2023
|
||
|
CFR |
21 CFR 556.34
Created by
admin on Fri Dec 15 15:05:18 UTC 2023 , Edited by admin on Fri Dec 15 15:05:18 UTC 2023
|
||
|
FDA ORPHAN DRUG |
94195
Created by
admin on Fri Dec 15 15:05:18 UTC 2023 , Edited by admin on Fri Dec 15 15:05:18 UTC 2023
|
||
|
LIVERTOX |
NBK548360
Created by
admin on Fri Dec 15 15:05:18 UTC 2023 , Edited by admin on Fri Dec 15 15:05:18 UTC 2023
|
||
|
NDF-RT |
N0000175481
Created by
admin on Fri Dec 15 15:05:18 UTC 2023 , Edited by admin on Fri Dec 15 15:05:18 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.1.2
Created by
admin on Fri Dec 15 15:05:18 UTC 2023 , Edited by admin on Fri Dec 15 15:05:18 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
F4216019LN
Created by
admin on Fri Dec 15 15:05:18 UTC 2023 , Edited by admin on Fri Dec 15 15:05:18 UTC 2023
|
PRIMARY | |||
|
16664
Created by
admin on Fri Dec 15 15:05:18 UTC 2023 , Edited by admin on Fri Dec 15 15:05:18 UTC 2023
|
PRIMARY | |||
|
F4216019LN
Created by
admin on Fri Dec 15 15:05:18 UTC 2023 , Edited by admin on Fri Dec 15 15:05:18 UTC 2023
|
PRIMARY | |||
|
m1473
Created by
admin on Fri Dec 15 15:05:18 UTC 2023 , Edited by admin on Fri Dec 15 15:05:18 UTC 2023
|
PRIMARY | Merck Index | ||
|
1012553
Created by
admin on Fri Dec 15 15:05:18 UTC 2023 , Edited by admin on Fri Dec 15 15:05:18 UTC 2023
|
PRIMARY | |||
|
220008
Created by
admin on Fri Dec 15 15:05:18 UTC 2023 , Edited by admin on Fri Dec 15 15:05:18 UTC 2023
|
PRIMARY | |||
|
7444
Created by
admin on Fri Dec 15 15:05:18 UTC 2023 , Edited by admin on Fri Dec 15 15:05:18 UTC 2023
|
PRIMARY | |||
|
2082
Created by
admin on Fri Dec 15 15:05:18 UTC 2023 , Edited by admin on Fri Dec 15 15:05:18 UTC 2023
|
PRIMARY | |||
|
430
Created by
admin on Fri Dec 15 15:05:18 UTC 2023 , Edited by admin on Fri Dec 15 15:05:18 UTC 2023
|
PRIMARY | RxNorm | ||
|
DB00518
Created by
admin on Fri Dec 15 15:05:18 UTC 2023 , Edited by admin on Fri Dec 15 15:05:18 UTC 2023
|
PRIMARY | |||
|
100000087712
Created by
admin on Fri Dec 15 15:05:18 UTC 2023 , Edited by admin on Fri Dec 15 15:05:18 UTC 2023
|
PRIMARY | |||
|
54965-21-8
Created by
admin on Fri Dec 15 15:05:18 UTC 2023 , Edited by admin on Fri Dec 15 15:05:18 UTC 2023
|
PRIMARY | |||
|
ALBENDAZOLE
Created by
admin on Fri Dec 15 15:05:18 UTC 2023 , Edited by admin on Fri Dec 15 15:05:18 UTC 2023
|
PRIMARY | |||
|
ALBENDAZOLE
Created by
admin on Fri Dec 15 15:05:18 UTC 2023 , Edited by admin on Fri Dec 15 15:05:18 UTC 2023
|
PRIMARY | Description: A white or almost white powder. Solubility: Practically insoluble in water; soluble in glacial acetic acid R; slightly soluble in acetone R, very slightly soluble in ethanol (~750 g/l) TS. Category: Anthelminthic. Storage: Albendazole should be kept in a well-closed container, protected from light. Additional information: Melting temperature, about 210?C, with decomposition. Requirement: Albendazole contains not less than 98.0% and not more than 101.0% of C12H15N3O2S, calculated with reference to the dried substance. | ||
|
D015766
Created by
admin on Fri Dec 15 15:05:18 UTC 2023 , Edited by admin on Fri Dec 15 15:05:18 UTC 2023
|
PRIMARY | |||
|
N0000191624
Created by
admin on Fri Dec 15 15:05:18 UTC 2023 , Edited by admin on Fri Dec 15 15:05:18 UTC 2023
|
PRIMARY | Cytochrome P450 1A Inducers [MoA] | ||
|
C47384
Created by
admin on Fri Dec 15 15:05:18 UTC 2023 , Edited by admin on Fri Dec 15 15:05:18 UTC 2023
|
PRIMARY | |||
|
3967
Created by
admin on Fri Dec 15 15:05:18 UTC 2023 , Edited by admin on Fri Dec 15 15:05:18 UTC 2023
|
PRIMARY | |||
|
SUB05295MIG
Created by
admin on Fri Dec 15 15:05:18 UTC 2023 , Edited by admin on Fri Dec 15 15:05:18 UTC 2023
|
PRIMARY | |||
|
CHEMBL1483
Created by
admin on Fri Dec 15 15:05:18 UTC 2023 , Edited by admin on Fri Dec 15 15:05:18 UTC 2023
|
PRIMARY | |||
|
albendazole
Created by
admin on Fri Dec 15 15:05:18 UTC 2023 , Edited by admin on Fri Dec 15 15:05:18 UTC 2023
|
PRIMARY | |||
|
103
Created by
admin on Fri Dec 15 15:05:18 UTC 2023 , Edited by admin on Fri Dec 15 15:05:18 UTC 2023
|
PRIMARY | |||
|
DTXSID0022563
Created by
admin on Fri Dec 15 15:05:18 UTC 2023 , Edited by admin on Fri Dec 15 15:05:18 UTC 2023
|
PRIMARY | |||
|
Albendazole
Created by
admin on Fri Dec 15 15:05:18 UTC 2023 , Edited by admin on Fri Dec 15 15:05:18 UTC 2023
|
PRIMARY | |||
|
259-414-7
Created by
admin on Fri Dec 15 15:05:18 UTC 2023 , Edited by admin on Fri Dec 15 15:05:18 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BINDER->LIGAND |
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
BINDER->LIGAND |
BINDING
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE INACTIVE -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
METABOLITE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
sum of impurities B and C: maximum 0.4 percent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
sum of impurities B and C: maximum 0.4 percent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||